General Information


DRACP ID  DRACP04469

Peptide Name  

Sequence  GRGDS

Sequence Length  5

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C17H30N8O9

Absent amino acids  ACEFHIKLMNPQTVWY

Common amino acids  G

Mass  56200

Pl  6.34

Basic residues  1

Acidic residues  1

Hydrophobic residues  0

Net charge  0

Boman Index  -2516

Hydrophobicity  -192

Aliphatic Index  0

Half Life 
  Mammalian: 1 hour
  Yeast: 2 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 1718779

Title  Arg-Gly-Asp constrained within cyclic pentapeptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1

Doi Not available

Year  1991

Literature 2

Pubmed ID 21269250

Title  Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation

Doi Not available

Year  2010

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  20030

DRACP is developed by Dr.Zheng's team.